» Articles » PMID: 23343665

Differential and Better Response to Deep Brain Stimulation of Chorea Compared to Dystonia in Huntington's Disease

Overview
Publisher Karger
Specialty Neurosurgery
Date 2013 Jan 25
PMID 23343665
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Huntington's disease (HD) is an autosomal dominant and progressive neurodegenerative syndrome characterized by motor, cognitive and psychiatric manifestations. Chorea and dystonia are features that may be troublesome to some patients and may potentially prove unresponsive to pharmacological treatments. There are several reports on the results of globus pallidus internus deep brain stimulation (DBS) surgery for HD. In these published cases, DBS was utilized mainly to treat disabling chorea. We report our experience with 2 HD cases treated with DBS. The cases illustrate a differential response with a better outcome in the choreic presentation compared to the dystonic presentation. Additionally, DBS worsened gait features in both cases.

Citing Articles

Advancements in surgical treatments for Huntington disease: From pallidotomy to experimental therapies.

Kim L, Kundu B, Moretti P, Lozano A, Rahimpour S Neurotherapeutics. 2024; 21(6):e00452.

PMID: 39304438 PMC: 11585891. DOI: 10.1016/j.neurot.2024.e00452.


Deep Brain Stimulation beyond the Clinic: Navigating the Future of Parkinson's and Alzheimer's Disease Therapy.

Senevirathne D, Mahboob A, Zhai K, Paul P, Kammen A, Lee D Cells. 2023; 12(11).

PMID: 37296599 PMC: 10252401. DOI: 10.3390/cells12111478.


Deep brain stimulation in Huntington's disease: a literature review.

Bonomo R, Elia A, Bonomo G, Romito L, Mariotti C, Devigili G Neurol Sci. 2021; 42(11):4447-4457.

PMID: 34471947 DOI: 10.1007/s10072-021-05527-1.


Does pallidal neuromodulation influence cognitive decline in Huntington's disease?.

Sanrey E, Macioce V, Gonzalez V, Cif L, Cyprien F, Seng E J Neurol. 2020; 268(2):613-622.

PMID: 32886253 DOI: 10.1007/s00415-020-10206-w.


Therapeutic Update on Huntington's Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies.

Dash D, Mestre T Neurotherapeutics. 2020; 17(4):1645-1659.

PMID: 32705582 PMC: 7851270. DOI: 10.1007/s13311-020-00891-w.